Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism
← catalyst calendarSponsored by MBX Biosciences (industry) · MBX — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
64actual
Sites
33
Countries
Argentina, Turkey (Türkiye), United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-08 | actual | When the study began enrolling |
| Primary completion | 2025-05-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-04 | actual | The whole study's end, after follow-up |
| First posted | 2024-06-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hypoparathyroidism
Interventions
- Drug: MBX 2109 — also filed as Canvuparatide
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFTo evaluate the effect of pooled weekly doses of MBX 2109 on the proportion of responder patients defined by serum calcium levels and treatment with active vitamin D and calcium supplements at Week 12/Visit 15
measured Week 12
Permalink · MBX's whole pipeline · Catalyst calendar · Every registered study · What changed